Akari Therapeutics Plc (AKTX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Akari Therapeutics Plc (AKTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8012
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company that develops treatments for rare and orphan autoimmune and inflammatory diseases. The company offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a and formation of C5b – 9. The company’s pipeline products include paroxysmal nocturnal hemoglobinuria, Guillain Barre Syndrome and atypical hemolytic uremic syndrome. Akari pipeline products include Coversin, Coversin LA, LTB4+C5, LTB4, LTBA LA, and bioamine inhibitors. The company operates in Switzerland, Israel, the UK and the US. Akari is headquartered in New York City, New York, the US.

Akari Therapeutics Plc (AKTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akari Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 11
Licensing Agreements 12
Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 12
Equity Offering 13
Akari Therapeutics Prices Public Offering of American Depositary Shares for USD17.4 Million 13
Celsus Therapeutics Raises USD75 Million in Private Placement of ADS 15
Celsus Therapeutics Completes Public Offering Of American Depositary Shares For US$8 Million 17
Celsus Therapeutics Completes Private Placement Of Shares For US$12.5 Million 19
Morria Biopharma Completes Private Placement Of Shares For US$0.8 Million 20
Morria Biopharma Completes Private Placement Of Units For US$1.5 Million 21
Acquisition 22
Celsus Therapeutics Acquires Volution Immuno Pharma 22
Akari Therapeutics Plc – Key Competitors 23
Akari Therapeutics Plc – Key Employees 24
Akari Therapeutics Plc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Sep 27, 2018: Akari announces second quarter 2018 financial results and business highlights 26
Aug 17, 2018: Akari announces first quarter 2018 financial results and update on its growing pipeline of phase II and phase III clinical trials 27
Mar 21, 2018: Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress 29
Corporate Communications 31
May 08, 2018: Akari Therapeutics: Resignation of CEO 31
Jan 23, 2018: Akari Therapeutics Strengthens Board with Two Senior Industry Appointments 32
Aug 21, 2017: Akari Therapeutics Announces Appointment of David Horn Solomon as CEO 33
May 30, 2017: Akari Therapeutics Announces Resignation of CEO 34
Product Approvals 35
Mar 30, 2017: Akari Therapeutics Announces FDA Fast Track Designation For Coversin 35
Clinical Trials 36
Jun 15, 2018: Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association 36
Feb 06, 2018: Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials 37
Dec 08, 2017: Akari Therapeutics Announces Phase II COBALT trial of Coversin in Patients with PNH Met the Primary Endpoint 38
Oct 11, 2017: Akari Therapeutics Announces Further Clinical Progress 39
Sep 21, 2017: Akari Therapeutics Announces Regulatory Progress Following FDA Meeting 40
Apr 27, 2017: Akari Therapeutics Announces Edisons Withdrawal of Edison Report titled “Akari’s Coversin matches Soliris in Phase II” 41
Apr 24, 2017: Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets 42
Jan 03, 2017: Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akari Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akari Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 11
Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 12
Akari Therapeutics Prices Public Offering of American Depositary Shares for USD17.4 Million 13
Celsus Therapeutics Raises USD75 Million in Private Placement of ADS 15
Celsus Therapeutics Completes Public Offering Of American Depositary Shares For US$8 Million 17
Celsus Therapeutics Completes Private Placement Of Shares For US$12.5 Million 19
Morria Biopharma Completes Private Placement Of Shares For US$0.8 Million 20
Morria Biopharma Completes Private Placement Of Units For US$1.5 Million 21
Celsus Therapeutics Acquires Volution Immuno Pharma 22
Akari Therapeutics Plc, Key Competitors 23
Akari Therapeutics Plc, Key Employees 24
Akari Therapeutics Plc, Other Locations 25
Akari Therapeutics Plc, Subsidiaries 25

List of Figures
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Akari Therapeutics Plc (AKTX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • University of British Columbia-製薬・医療分野:企業M&A・提携分析
    Summary University of British Columbia (UBC) is a research institute that offers educational services. The university provides undergraduate, graduate educational programs, and research programs through its schools and faculties. It provides cultural, recreational and social activities for its stude …
  • PricewaterhouseCoopers LLP (UK):企業の戦略的SWOT分析
    PricewaterhouseCoopers LLP (UK) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • CorEnergy Infrastructure Trust, Inc. (CORR)-石油・ガス分野:企業M&A・提携分析
    Summary CorEnergy Infrastructure Trust, Inc. (CorEnergy) is an energy infrastructure real estate investment trust. The company owns assets in the midstream and downstream US energy sectors that perform functions, such as pipelines, storage terminals, and transmission and distribution assets. Its por …
  • Talwalkars Better Value Fitness Ltd (TALWALKARS):企業の財務・戦略的SWOT分析
    Talwalkars Better Value Fitness Ltd (TALWALKARS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • The Advisory Board Company (ABCO):企業の財務・戦略的SWOT分析
    The Advisory Board Company (ABCO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Nippon Paint Holdings Co Ltd (4612):企業の財務・戦略的SWOT分析
    Nippon Paint Holdings Co Ltd (4612) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Praxair Inc (PX)-エネルギー分野:企業M&A・提携分析
    Summary Praxair Inc (Praxair) is a producer and supplier of industrial gases. The company offers atmospheric gases including oxygen, nitrogen, argon and rare gases, and process gases such as carbon dioxide, helium, hydrogen, electronic gases, specialty gases and acetylene. It also designs and builds …
  • South Jersey Industries Inc (SJI):石油・ガス:M&Aディール及び事業提携情報
    Summary South Jersey Industries Inc (SJI) is an energy services holding company that sources and supplies natural gas and electricity. It develops, owns, and operates on-site energy production facilities. The company provides wholesale commodity marketing and fuel management services; and also offer …
  • Telia Company (TELIA):企業の財務・戦略的SWOT分析
    Telia Company (TELIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Boparan Holdings Ltd:企業の戦略的SWOT分析
    Boparan Holdings Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Harvard Medical School-製薬・医療分野:企業M&A・提携分析
    Summary Harvard Medical School (HMS), a subsidiary of Harvard University is a medical institute that offers education, research and clinical care services. The institute offers various degree programs such as bachelor's program, master's program, PhD program, and continuing education. It offers prog …
  • Health Net, LLC.:企業の戦略・SWOT・財務分析
    Health Net, LLC. - Strategy, SWOT and Corporate Finance Report Summary Health Net, LLC. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Michigan Public Power Agency:企業の戦略的SWOT分析
    Michigan Public Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Hutchinson SA:企業の戦略的SWOT分析
    Hutchinson SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Kuwait Energy Plc:石油・ガス:M&Aディール及び事業提携情報
    Summary Kuwait Energy Plc (Kuwait Energy) is an independent oil and gas company that carries out exploration, appraisal, development and production of hydrocarbons. The company operates wide range of oil and gas assets in Middle East and North Africa (MENA) region. It has assets across Egypt, Yemen, …
  • Admedes GmbH:企業の戦略的SWOT分析
    Admedes GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • University of Texas Health Science Center at Houston-製薬・医療分野:企業M&A・提携分析
    Summary University of Texas Health Science Center at Houston (UTHealth), a subsidiary of University of Texas System is an educational institution that provides research, education and patient care services. The university operates with schools of biomedical informatics, biomedical sciences, dentistr …
  • University of New Mexico:製薬・医療:M&Aディール及び事業提携情報
    Summary University of New Mexico (UNM) is an educational service provider that offers bachelors, masters, doctoral and professional degree programs in various fields. The university offers programs such as evening and weekend degree programs, continuing education, extended learning, Latin American s …
  • C.H. Robinson Worldwide, Inc.:企業の戦略・SWOT・財務情報
    C.H. Robinson Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report Summary C.H. Robinson Worldwide, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG, BAY 1905254, COM902 and TIGIT; and CGEN-XXXX/Myeloid and autoimmune diseases …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆